This study is in progress, not accepting new patients
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCSD UCSF
- Dates
- study startedcompletion around
- Principal Investigator
- by Adil Daud (ucsf)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Adil Daud (ucsf)
Professor, Medicine, School of Medicine. Authored (or co-authored) 201 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Novartis Pharmaceuticals
- ID
- NCT02974725
- Phase
- Phase 1 research study
- Study Type
- Interventional
- Participants
- About 241 people participating
- Last Updated